On July 19, 2022, the DPH shared updated clinical guidance for COVID-19 therapeutics. Nirmatrelvir/ritonavir (PAXLOVID) continues to be the preferred treatment for most patients with mild-to-moderate COVID-19 at high risk of progression to severe disease and continues to be widely available and in adequate supply in Massachusetts.
Read more